dalazatide

Dalazatide is a 37-amino acid synthetic peptide derived from the ShK peptide originally isolated from the venom of the Caribbean sea anemone. It is a first-in-class, selective inhibitor of the voltage-gated Kv1.3 potassium channel. The Kv1.3 channel is highly upregulated on effector memory T-cells (TEM cells), which are key mediators in autoimmune diseases such as psoriasis and multiple sclerosis. By blocking this channel, dalazatide suppresses chronically activated memory T cells without affecting naïve or central memory T cells, potentially reducing inflammation and tissue damage while preserving general immune function. Dalazatide has been investigated in phase 1 clinical trials for plaque psoriasis and has shown efficacy in preclinical models of multiple sclerosis and other autoimmune conditions including lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes, and ANCA-associated vasculitis[1][2][4][6][8].

Other names

dalazatideShK-186ShK186ShK 186